IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-7.92%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$443M
AUM Growth
+$443M
(-1.2%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-34.63%
Top 10 Holdings %
Top 10 Hldgs %
47.3%
Holding
81
New
8
Increased
12
Reduced
20
Closed
11
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$19.3M |
| 2 |
Novavax
NVAX
|
$18.5M |
| 3 |
Zai Lab
ZLAB
|
$8.59M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$7.65M |
| 5 |
Sanofi
SNY
|
$7.64M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$51.4M |
| 2 |
Amgen
AMGN
|
$38.1M |
| 3 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$29.3M |
| 4 |
Insmed
INSM
|
$28.8M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$25.7M |
Sector Composition
| 1 | Healthcare | 99.23% |
| 2 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Dyne Therapeutics
DYN
$1.92B
| $1.16M | 0.26% | 476,000 | – | – |
|
52
Krystal Biotech
KRYS
$4.27B
| $1.11M | 0.25% | 45,000 | – | – |
|
53
Amicus Therapeutics
FOLD
$2.34B
| $1.09M | 0.25% | 94,600 | – | – |
|
54
Gilead Sciences
GILD
$140B
| $1.08M | 0.24% | 88,784 -194,000 | -69% | -$2.36M |
|
55
Oric Pharmaceuticals
ORIC
$994M
| $905K | 0.2% | 176,217 +23,217 | +15% | +$119K |
|
|
BPMC
56
DELISTED
Blueprint Medicines
BPMC
| $881K | 0.2% | 19,500 | – | – |
|
57
Immunovant
IMVT
$2.56B
| $851K | 0.19% | 60,000 | – | – |
|
58
Fulcrum Therapeutics
FULC
$351M
| $833K | 0.19% | 82,741 +21,741 | +36% | +$219K |
|
59
Allogene Therapeutics
ALLO
$251M
| $747K | 0.17% | 50,000 | – | – |
|
60
Relmada Therapeutics
RLMD
$37.2M
| $741K | 0.17% | 10,000 | – | – |
|
61
Agios Pharmaceuticals
AGIO
$2.19B
| $707K | 0.16% | 21,500 | – | – |
|
62
PTC Therapeutics
PTCT
$3.92B
| $617K | 0.14% | 411,000 -38,000 | -8% | -$57K |
|
63
Intellia Therapeutics
NTLA
$1.22B
| $511K | 0.12% | 24,000 | – | – |
|
64
AnaptysBio
ANAB
$569M
| $348K | 0.08% | 10,000 | – | – |
|
65
Guardant Health
GH
$8.41B
| $271K | 0.06% | 74,500 | – | – |
|
66
BioMarin Pharmaceuticals
BMRN
$11.2B
| $235K | 0.05% | 79,656 -25,500 | -24% | -$75.2K |
|
|
SGEN
67
DELISTED
Seagen Inc. Common Stock
SGEN
| $225K | 0.05% | 76,200 -37,000 | -33% | -$109K |
|
68
Nkarta
NKTX
$151M
| $209K | 0.05% | 10,034 -30,166 | -75% | -$628K |
|
|
TSVT
69
DELISTED
2seventy bio
TSVT
| $94K | 0.02% | 3,666 | – | – |
|
70
BridgeBio Pharma
BBIO
$9.89B
| – | – | -52,800 | Closed | -$881K |
|
71
Black Diamond Therapeutics
BDTX
$157M
| – | – | -44,000 | Closed | -$235K |
|
72
Biogen
BIIB
$19.4B
| – | – | -47,500 | Closed | -$11.4M |
|
73
CRISPR Therapeutics
CRSP
$4.71B
| – | – | -108,200 | Closed | -$8.19M |
|
74
Exact Sciences
EXAS
$8.98B
| – | – | -10,700 | Closed | -$833K |
|
75
Exelon
EXC
$44.1B
| – | – | -546,534 | Closed | -$9.99M |
|